Sector News

Trump pledges 'new system' to bring drug prices down

March 7, 2017
Life sciences

After House Republicans unveiled a new healthcare bill that’s all but silent on drug pricing, President Donald Trump on Tuesday promised that he hasn’t abandoned his pledge to take action.

Trump first tweeted Tuesday that “getting rid of state lines, which will promote competition, will be in phase 2 & 3 of healthcare rollout,” apparently referring to geographic restrictions on insurers—and filling in what he sees as a gap in the Obamacare repeal-and-replace effort.

Then, five minutes later, he switched to pharma.

It’s the latest in a series of political developments—and Trump pronouncements—that have kept industry-watchers on edge. The president has made repeated promises to “bring down” drug prices, and has backed some ideas, such as Medicare price negotiation and drug importation, that drugmakers have fought off in the past. As yet, however, the administration hasn’t set out specific proposals to tackle high drug prices in the U.S.

Reacting to Tuesday’s presidential tweet, Evercore ISI analyst Umer Raffat wondered what Trump meant by bolstering competition. He noted that brand vs. generic competition exists and direct brand vs. brand competition requires interchangeable meds. That’s possible in some therapeutic areas, but not all, he pointed out.

“Reality is, we just don’t know until something definitive is put out,” Raffat said.

Before he took office in January, Trump said the drug industry was “getting away with murder.” He promised more competitive “bidding” to save the U.S. billions in healthcare costs. That promise left drugmakers and analysts scratching their heads about what sort of competitive bidding process could apply to drugs.

After that, at a White House meeting with industry representatives, the president softened his tone to say that pharma companies have done a “terrific job over the years, but we have to get prices down for a lot of reasons.” Top CEOs and trade organization leaders came away from that meeting apparently cheered by talk of tax reform, and less worried about pricing moves.

Still, the industry’s pricing stance is quite different from Trump’s public comments. In the wake of Trump’s January screed, Pfizer CEO Ian Read said the president likely “hasn’t been briefed” on the competition dynamics in the drug industry. Read said “it’s a very complicated industry,” one with a “huge amount of bidding and extremely aggressive purchasing.”

While the drug pricing debate rolls on, pharma could be working to leverage its job-creation argument in negotiations with a White House that has put a strong emphasis on that subject, according to Raffat.

Biopharma shares were trading slightly down late Tuesday morning after the tweet.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach